Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have been a crucial part of the healthcare industry for decades. These drugs are used to treat viral infections by inhibiting the growth of the virus. In Europe, the market for antiviral drugs has been growing steadily in recent years.
Customer preferences: Customers in Europe are increasingly concerned about their health and are willing to invest in medications that can help them fight viral infections. This has led to an increase in demand for antiviral drugs in the region. Additionally, the aging population in Europe is more susceptible to viral infections, which has further fueled the demand for antiviral drugs.
Trends in the market: The antiviral drugs market in Europe is dominated by a few major players. These companies are constantly investing in research and development to improve the efficacy of their drugs and develop new treatments for viral infections. One of the major trends in the market is the development of antiviral drugs that are more effective against a wider range of viruses. Another trend is the development of drugs that can be taken orally, making them more convenient for patients.
Local special circumstances: Different countries in Europe have different healthcare systems and regulations, which can affect the availability and pricing of antiviral drugs. In countries with universal healthcare systems, antiviral drugs may be more accessible and affordable for patients. In countries with more privatized healthcare systems, the cost of antiviral drugs may be higher, which could limit their accessibility for some patients.
Underlying macroeconomic factors: The growth of the antiviral drugs market in Europe is also influenced by macroeconomic factors such as population growth, GDP growth, and government healthcare spending. As the population in Europe continues to age, the demand for antiviral drugs is likely to increase. Additionally, as GDP grows, people are more likely to invest in their health, which could further fuel the demand for antiviral drugs. Finally, government healthcare spending can also have a significant impact on the availability and pricing of antiviral drugs in different countries in Europe.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
